[HTML][HTML] Benefits of adding fluticasone propionate/salmeterol to tiotropium in moderate to severe COPD
NA Hanania, GD Crater, AN Morris, AH Emmett… - Respiratory …, 2012 - Elsevier
BACKGROUND: Combining maintenance medications with different mechanisms of action
may improve outcomes in COPD. In this study we evaluated the efficacy and safety of …
may improve outcomes in COPD. In this study we evaluated the efficacy and safety of …
Longterm survival among patients with scleroderma-associated pulmonary arterial hypertension treated with intravenous epoprostenol
…, FM Wigley, KM Kral, IH Raphiou, GD Crater - The Journal of …, 2009 - jrheum.org
Objective. Pulmonary arterial hypertension (PAH) remains challenging to treat, especially in
association with scleroderma. We examined survival rates among patients with PAH in …
association with scleroderma. We examined survival rates among patients with PAH in …
A phase 2 multiple ascending dose study of the inhaled pan-JAK inhibitor nezulcitinib (TD-0903) in severe COVID-19
Severe coronavirus disease 2019 (COVID-19) is characterised by pneumonia with excessive
systemic inflammation, referred to as a “cytokine storm” [1–3]. Dexamethasone treatment …
systemic inflammation, referred to as a “cytokine storm” [1–3]. Dexamethasone treatment …
[HTML][HTML] Nebulized versus dry powder long-acting muscarinic antagonist bronchodilators in patients with COPD and suboptimal peak inspiratory flow rate
…, EJ Moran, S Pendyala, GD Crater - … Diseases: Journal of …, 2019 - ncbi.nlm.nih.gov
Background: Patients with chronic obstructive pulmonary disease (COPD) and suboptimal
peak inspiratory flow rate (sPIFR) may not benefit optimally from dry powder inhalers (DPI) …
peak inspiratory flow rate (sPIFR) may not benefit optimally from dry powder inhalers (DPI) …
[HTML][HTML] Effect of fluticasone propionate/salmeterol on arterial stiffness in patients with COPD
…, DB Rubin, AH Emmett, MJ Cicale, GD Crater… - Respiratory …, 2011 - Elsevier
BACKGROUND: COPD is associated with increased arterial stiffness which may in part
explain the cardiovascular morbidity observed in the disease. A causal relationship between …
explain the cardiovascular morbidity observed in the disease. A causal relationship between …
Effects of CB1R inverse agonist, INV‐202, in patients with features of metabolic syndrome. A randomized, placebo‐controlled, double‐blind phase 1b study
GD Crater, K Lalonde, F Ravenelle… - Diabetes, Obesity …, 2024 - Wiley Online Library
Aims To evaluate the clinical safety, tolerability, and pharmacokinetic and pharmacodynamic
profile of the novel cannabinoid receptor‐1 (CB1R) inverse agonist, INV‐202, in adults with …
profile of the novel cannabinoid receptor‐1 (CB1R) inverse agonist, INV‐202, in adults with …
[HTML][HTML] Safety, tolerability, pharmacodynamics and pharmacokinetics of umeclidinium and vilanterol alone and in combination: a randomized crossover trial
…, BM Jean-Francois, AF Preece, J Blowers, GD Crater… - PLoS …, 2012 - journals.plos.org
Umeclidinium bromide (GSK573719; UMEC), a new long-acting muscarinic receptor antagonist
(LAMA), is in development with vilanterol (GW642444; VI), a selective long-acting β 2 …
(LAMA), is in development with vilanterol (GW642444; VI), a selective long-acting β 2 …
Prevalence of airway obstruction assessed by lung function questionnaire
…, AA Dalal, IH Raphiou, BA Prillaman, GD Crater… - Mayo Clinic …, 2011 - Elsevier
… Crater MD h , Michael J. Cicale MD h , Douglas W. Mapel MD i … Ms Prillaman and Drs Dalal,
Crater, Raphiou, and Cicale are GlaxoSmithKline employees and own stock in the company. …
Crater, Raphiou, and Cicale are GlaxoSmithKline employees and own stock in the company. …
[HTML][HTML] Fluticasone propionate/salmeterol 250/50 μg versus salmeterol 50 μg after chronic obstructive pulmonary disease exacerbation
JA Ohar, GD Crater, A Emmett, TJ Ferro, AN Morris… - Respiratory …, 2014 - Springer
Background Inhaled long-acting beta 2 agonists used alone and in combination with an
inhaled corticosteroid reduce the risk of exacerbations in patients with stable COPD. However, …
inhaled corticosteroid reduce the risk of exacerbations in patients with stable COPD. However, …
[HTML][HTML] Observational study of the outcomes and costs of initiating maintenance therapies in patients with moderate exacerbations of COPD
… AD Dalal and GD Crater are employees of GlaxoSmithKline (GSK) and own company stock.
MB Shah, AO D’Souza and OE Lunacsek are employees of Xcenda, LLC, a company that …
MB Shah, AO D’Souza and OE Lunacsek are employees of Xcenda, LLC, a company that …